Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Inhaled Delivery Consulting AB
AB
Active
Org 5594054032
Lovartsgatan 13, 211 74
Malmö
Research and experimental development on natural sciences and engineering
· NACE 7210
Est. 2022
0 employees
Watchlist
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Inhaled Delivery Consulting AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
1M
2M
3M
3M
3M
2024
1M
2025
EBITDA
SEK millions
0M
1M
1M
2M
2M
2M
2024
0M
2025
Income statement
SEK thousands
Item
2024
2025
Revenue
2 564
1 379
Staff expenses
−333
−1 000
EBITDA
2 130
322
Depreciation & amort.
—
−8
EBIT
2 130
315
Net financials
−26
10
Profit before tax
2 103
324
Tax
−433
−67
Net profit
1 670
257
Balance sheet
SEK thousands
Item
2024
2025
Total assets
2 112
2 769
Equity
1 695
1 952
Long-term debt
25
25
Short-term debt
392
792
Total debt
417
817
Financial ratios
5-year trend
EBITDA margin
23.4%
This company
15.8%
Market median
+48% vs market
2024
2025
Equity ratio
70.5%
This company
38.2%
Market median
+85% vs market
2024
2025
Return on equity
13.2%
This company
18.4%
Market median
+28% vs market
2024
2025
Net profit margin
18.7%
This company
8.1%
Market median
+131% vs market
2024
2025
Asset turnover
0.50×
This company
1.12×
Market median
-55% vs market
2024
2025
Debt / equity
0.42×
This company
0.62×
Market median
+32% vs market
2024
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2022-11-10 – 2024-04-30
View
PDF
More on Inhaled Delivery Consulting AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
